Evaluating the Efficacy of Semaglutide in Preventing Chronic Kidney Disease Among Type 2 Diabetics
|
Reviewed & Translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on August 7th, 2024
|
The risk of chronic kidney disease is significantly higher in patients with type 2 diabetes. Previous studies have shown that those treated with renin–angiotensin system inhibitors and sodium–glucose cotransporter 2 inhibitors have a reduced risk of developing chronic kidney disease. Given the growing popularity of glucagon-like peptide 1 (GLP-1) agonists like semaglutide, a study was conducted to evaluate its impact on the risk of chronic kidney disease in patients with type 2 diabetes.
The clinical study included a total of 3533 patients who had been diagnosed with type 2 diabetes and have a high risk of chronic kidney disease. The cohort’s average glycated hemoglobin level was 7.8%, and the average estimated glomerular filtration rate (eGFR) of the participants was 47.0 mL/min. The participants were randomly assigned to be treated with either placebo or semaglutide, which was administered intradermally at an initial dose of 0.25 mg per week for 4 weeks, which is escalated to 0.5 mg per week for another 4 weeks, followed by a maintenance dose of 1.0 mg per week throughout the remainder of the treatment period. After a median follow-up duration of 3.4 years, the researchers found that those who used semaglutide experienced a lower risk of death due to cardiovascular disease and less reductions in estimated glomerular filtration rate. Additionally, those who were treated with semaglutide experienced less annual reduction in eGFR with a between-group difference of 1.16 ml per minute per 1.73 square meter.
The clinical study included a total of 3533 patients who had been diagnosed with type 2 diabetes and have a high risk of chronic kidney disease. The cohort’s average glycated hemoglobin level was 7.8%, and the average estimated glomerular filtration rate (eGFR) of the participants was 47.0 mL/min. The participants were randomly assigned to be treated with either placebo or semaglutide, which was administered intradermally at an initial dose of 0.25 mg per week for 4 weeks, which is escalated to 0.5 mg per week for another 4 weeks, followed by a maintenance dose of 1.0 mg per week throughout the remainder of the treatment period. After a median follow-up duration of 3.4 years, the researchers found that those who used semaglutide experienced a lower risk of death due to cardiovascular disease and less reductions in estimated glomerular filtration rate. Additionally, those who were treated with semaglutide experienced less annual reduction in eGFR with a between-group difference of 1.16 ml per minute per 1.73 square meter.